Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
Advisory, awaiting, axonal, bamlanivimab, baricitinib, bi, billing, calculated, ceiling, child, compel, comply, Connecticut, covered, degeneration, diagnosed, Disarm, dispensing, entity, etesevimab, flat, Fournier, gangrene, Hampshire, HHS, hospitalized, Instance, Kabi, long, markup, meaningful, minimal, modest, monotherapy, notably, point, preferable, principle, prohibiting, protein, provisionally, questioning, reinstated, remdesivir, returning, Sept, sintilimab, somatostain, sooner, spike, Stamford, sum, telehealth, unfunded, unsuccessfully, variety, venture, violate, voluntary, wholly
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view